If the risk of mass delistings is as real as some claim, with the obvious implications for patients, then surely it needs to be part of any forum hosted by or even involving the industry?
Surely the best 'patient view' is one that is fully informed?
September 2, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
New treatment listed on PBS, offering twice-yearly dosing for Australians with relapsing MS
January 9, 2026 - - Latest News -
The value of looking back and the importance of seeing the 'smoke signals' on reform
January 8, 2026 - - Latest News -
Vaxxas appoints former global vaccines leader to head global commercialisation push
January 8, 2026 - - Australian Biotech -
Reform was justified because a committee prioritising clinical considerations was 'culturally' problematic
January 4, 2026 - - Latest News -
AdAlta and SHcell launch cancer collaboration to progress breakthrough CAR-T therapy
January 2, 2026 - - Australian Biotech -
Cabinet documents from the year that led to transformational changes
January 1, 2026 - - Latest News -
US pricing push gets real with Australia included in comparison list
December 22, 2025 - - Latest News

